Literature DB >> 14633083

Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two-drug crossover study.

Isao Ikemoto1, Hiroshi Kiyota, Yukihiko Ohishi, Kazuhiro Abe, Hirokazu Goto, Kouichi Kishimoto, Kenta Miki.   

Abstract

BACKGROUND: The aim of the study presented here was to stratify drug therapy for patients with benign prostatic hyperplasia (BPH) displaying various voiding symptoms.
METHODS: Two different alpha1-adrenoceptor antagonists; tamsulosin hydrochloride (Tam) and naftopidil (Naf ), were administered to 96 patients with BPH for 8 weeks in a crossover study.
RESULTS: With the administration of both drugs, the International Prostate Symptom Score (I-PSS) significantly decreased and the maximum urinary flow significantly increased. Whereas Naf monotherapy decreased the I-PSS for storage symptoms, Tam monotherapy decreased the I-PSS for voiding symptoms. In both the Naf-to-Tam and Tam-to-Naf groups, crossover was effective when the initial drug was judged subjectively and objectively to have been ineffective. Compliance was acceptable with both drugs.
CONCLUSION: Our results show that either Naf or Tam can be used to treat patients on the basis of objective and subjective assessment of voiding symptoms. Our findings should be helpful for patient guidance and treatment of BPH.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14633083     DOI: 10.1046/j.1442-2042.2003.00712.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  15 in total

Review 1.  Alpha1-adrenoceptor subtypes and lower urinary tract symptoms.

Authors:  Debra A Schwinn; Claus G Roehrborn
Journal:  Int J Urol       Date:  2008-03       Impact factor: 3.369

Review 2.  Subtypes of alpha1-adrenoceptors in BPH: future prospects for personalized medicine.

Authors:  Yoshiyuki Kojima; Shoichi Sasaki; Yutaro Hayashi; Gozoh Tsujimoto; Kenjiro Kohri
Journal:  Nat Clin Pract Urol       Date:  2009-01

3.  Clinical efficacy of a loading dose of naftopidil for patients with benign prostate hyperplasia.

Authors:  Yasuhito Funahashi; Ryohei Hattori; Yoshihisa Matsukawa; Tomonori Komatsu; Naoto Sassa; Momokazu Gotoh
Journal:  World J Urol       Date:  2010-03-23       Impact factor: 4.226

4.  Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasia.

Authors:  Erkan Karadağ; Sedat Öner; Yasemin U Budak; Özcan Atahan
Journal:  Int Urol Nephrol       Date:  2011-04-08       Impact factor: 2.370

Review 5.  Evaluation of Alpha 1 Adrenoceptor Antagonist Dose Increase Therapy: An Essential Strategy for Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.

Authors:  Masaki Watanabe; Satoshi Yamaguchi; Hidehiro Kakizaki; Naoki Hirabayashi; Hironori Ishida
Journal:  Curr Urol       Date:  2020-10-13

Review 6.  Does anticholinergic medication have a role in treating men with overactive bladder and benign prostatic hyperplasia?

Authors:  Kyu-Sung Lee; Hye Won Lee; Deok Hyun Han
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-03       Impact factor: 3.000

7.  The role of naftopidil in the management of benign prostatic hyperplasia.

Authors:  Noboru Hara; Takaki Mizusawa; Kenji Obara; Kota Takahashi
Journal:  Ther Adv Urol       Date:  2013-04

8.  Benign prostatic hyperplasia: from bench to clinic.

Authors:  Tag Keun Yoo; Hee Ju Cho
Journal:  Korean J Urol       Date:  2012-03-19

9.  Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia.

Authors:  Naoya Masumori
Journal:  Ther Clin Risk Manag       Date:  2011-06-23       Impact factor: 2.423

10.  Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.

Authors:  Eu Chang Hwang; Shreyas Gandhi; Jae Hung Jung; Mari Imamura; Myung Ha Kim; Ran Pang; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2018-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.